News:

Here we provide you with news articles, blogs and tweets on the key aspects of our bioinformatics and drug resistance work.

In this new section of the bioafrica.net website, we disseminate printed and online media coverage of our work and its application in everyday life.


News Latest News

EurekaAlert!


CD4+ T-cell count useful to assess antiretroviral therapy response in HTLV-1/HIV patients?

EurekaAlert! - 2017-03-17

News coverage and clinical management implication of our recent HIV/HTLV co-infection manuscript, Current HIV Research, 2017


Click on the CD4 image to access our publication

The authors compared the CD4+ T-cell counts and HIV-1 RNA viral loads of 383 patients who were either mono-infected with HIV or co-infected with HTLV-1/HIV. They confirmed that co-infected patients were more likely to have higher CD4+ T-cell counts prior to treatment initiation with no immunologic benefit--a result that has been well documented in scholarly literature. Any differences in the CD4+ T-cell counts were expected to disappear once the co-infected and mono-infected patients began to fail their antiretroviral therapy (ART) regimens.

Instead, the authors found that HTLV-1/HIVco-infected patients continued to have elevated CD4+ T-cell counts, on average 115 cells/uL higher than their HIV mono-infected counterparts, over the two-year study period. But when the authors compared the HIV viral loads over the same period, they could not find any statistically significant difference between the two groups of patients.

HIV viral load testing is currently recommended by the World Health Organization (WHO) as an accurate strategy for monitoring a patient's response to ART. Nevertheless, CD4+ T-cell testing is often used in resource-limited settings because it is perceived to be more affordable. The continued use of CD4+ T-cell testing has implications for the clinical management of HIV-positive patients. Results from the present study suggest that HTLV-1/HIV co-infection could delay the identification of patients who are failing ART with adverse consequences.

Against this background, recent scientific research has begun to show that HIV viral load testing can be both an accurate and cost-effective treatment monitoring strategy. The present study was based in the KwaZulu-Natal province of South Africa and used patient data from a poor and rural community at the epicentre of the global HIV epidemic.

This article by Dr. Alain Vandormael et al has been published in Current HIV Research, Volume 15, 2017

Links:

https://www.eurekalert.org/pub_releases/2017-03/bsp-ctc031717.php

Publication cited

CD4+ T-cell count may not be a useful strategy to monitor antiretroviral therapy response in HTLV-1/HIV co-infected patients. Vandormael A, Rego F, Danaviah S, Alcantara L, Boulware D, de Oliveira T, Current HIV Research (2017), :doi: 10.2174/1570162X15666170216114917.

15 minutes, All news...

Why KRISP? KRISP challenges the status quo to create a scientific environment in South Africa that drives innovations & reverses the brain drain.
From Why KRISP?, date: 2017-12-31

Even with easy access to ARVs, only one in three HIV-positive people will seek them
From KRISP News, date: 2017-12-05

South Africans with HIV miss out on the benefits of early treatment due to a fear of stigma
From KRISP News, date: 2017-12-02
15 minutes, All news...


Page design updated by Tulio de Oliveira, 2015